AlphaFold predicted structure
AGXT · P21549

Mean pLDDT
98.3/ 100
Very high
392 residues
Confidence breakdown
- Very high(≥ 90)99%
- Confident(70–90)1%
- Low(50–70)1%
- Very low(< 50)0%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
alanine--glyoxylate aminotransferase
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
DDG2P
BIALLELIC, autosomal or pseudoautosomalHereditary neuropathy or pain disorder
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalNephrocalcinosis or nephrolithiasis
BIALLELIC, autosomal or pseudoautosomalPeroxisomal disorders
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalHereditary neuropathy
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomal+2 more panels — install the extension to see the full list inline on any page.
primary hyperoxaluria type 1
primary hyperoxaluria
alanine glyoxylate aminotransferase deficiency
hereditary disease
Hyperoxaluria
nephrocalcinosis
nephrolithiasis
nephrotic syndrome
Abnormality of metabolism/homeostasis
cardiac arrhythmia
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Alanine--glyoxylate aminotransferase
Peroxisomal aminotransferase that catalyzes the transamination of glyoxylate to glycine and contributes to the glyoxylate detoxification (PubMed:10960483, PubMed:12777626, PubMed:23229545, PubMed:24055001, PubMed:26149463). Also catalyzes the transamination between L-serine and pyruvate and contributes to gluconeogenesis from the L-serine metabolism (PubMed:10347152)
AGXT · P21549

Mean pLDDT
98.3/ 100
Very high
392 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0